# Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

> **NCT04220944** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Hepatic Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **PROCEDURE:** Microwave Ablation
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT04220944
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-01
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220944, "Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04220944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*